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Abstract 
Aim: Recent studies point at the crucial role of epigenetic mechanisms in the development of 
multifactorial diseases such as periodontitis and diabetes mellitus (DM) type 2. In addition, 
circulatory microRNAs (miRs) have emerged as novel biomarkers for various diseases. Aim 
of this study was to investigate the levels of miR-146a and miR-155 and superoxide 
dismutase (SOD) activity in gingival crevicular fluid (GCF) of periodontitis patients with 
(CPDM) and without (CP) DM type 2 as well as in periodontally healthy, control groups 
(PHDM and PH, respectively). 
Material and methods: miR modulation was analyzed using quantitative real-time PCR 
while SOD activity was measured spectrophotometrically. 
Results: The upregulation of miR-146a and miR-155 was observed in CP and  
CPDM  patients baseline while the levels decreased after six weeks of the non-surgical 
therapy to the levels comparable to PH and PHDM, respectively. Expression levels of miRs 
positively correlated with SOD activity. Levels of miR-146a were higher in PHDM compared 
to PH patients.  Multivariate analysis revealed that levels of miR-146a and miR-155 were 
significantly associated with periodontitis when adjusting for age and gender.  
Conclusions: miR-146a and miR-155 may be consider as possible novel biomarkers for 
periodontitis in nondiabetic and type 2 diabetic patients. 
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Clinical Relevance  
Scientific rationale for the study: miRs as epigenetic regulators are appreciated as key 
players in the development of multifactorial diseases such as periodontitis and DM and 
represent an attractive new class of specific biomarkers. No previous study reported miRs in 
GCF from patients with periodontitis and DM. 
Principal findings: Expression levels of miR-146a and miR-155 were significantly increased 
in GCF of periodontitis patients with/without DM type 2 relative to healthy while decreased 
after non-surgical periodontal therapy. 
Practical implications: Present results imply that miR-146a and miR-155 in GCF could be 
potential biomarkers for periodontitis in nondiabetic as well as type 2 diabetic patients  
 
Introduction 
Periodontal disease is a set of bacteria-induced inflammatory diseases reflecting disturbance 
in interactions between microbials and host immunological responses. It has been reported 
that diabetes mellitus (DM) represents established risk factor for periodontitis but also, 
periodontitis adversely affect glycemic control in patients with DM contributing to the 
development of diabetic complications (Mealey & Oates 2006). Moreover, it has been shown 
that periodontal treatment could stabilize and even improve serum glucose levels in patients 
with DM (Noor et al. 
2015, Sima & Glogauer 2013, Teeuw et al. 2010) 
 The mounting evidence suggests that interrelationship between DM and periodontal disease, 
based on intracellular level, reflects vicious circle between oxidative stress and inflammation 
(Monea et al. 2014, Patil et al. 2016). However, the question rises which entities could be 
common regulators of these pathological processes, at the molecular level. In the light of 
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recent appreciation of epigenetics as one of the key player in the development of 
multifactorial diseases such as DM and periodontal disease (Ling & Groop 2009, Keating et 
al. 2016, Martins et al. 2016, Larsson et al. 2015), microRNAs (miRs), might acting as 
epigenetic regulators, draw an attention . miRs are small, non-coding RNAs that can suppress 
expression of a variety of genes thereby orchestrating a number of processes, such as host cell 
immune responses (Moffatt & Lamont 2011) including antibacterial (Li et al. 2016) and 
antiinflammatory as well as antioxidative (Hulsmans et al. 2011).  It is noteworthy that 
circulating miRs (in serum, saliva and other body fluids), due to their stability and distinctive 
function, have an advantage of being biomarkers compared with other biomarkers such as 
proteins or bacterial products (Kim et al. 2015). It is noteworthy that  salivary miRs have 
been evaluated as diagnostic biomarkers for oral squamous  cell carcinomas (Zahran et al. 
2015). On the other side, since miR activity and function could be modified in patients by 
pharmacological modulation, they are considered to be attractive therapeutic targets in a 
variety of diseases, among them DM micro - and macrovascular complications (van Rooij et 
al. 2012). In this research we focused on the two immunomodulatory miRs, miR-146a and 
miR-155, which are co-induced in many cell types responding to microbial 
lipopolysaccharide, facilitating a negative feedback control of NFkB target genes which 
encode various mediators of inflammation (Taganov et al. 2006, Ma et al. 2011) and involved 
in oxidative stress by targeting superoxide dismutase (SOD) (Ji et al. 2013).  Noteworthy, 
periodontitis patients had higher gingival tissue levels of miR-146a accompanied with the 
reduced levels of inflammatory cytokines than healthy (Motedayyen et al. 2015). We aimed 
to quantify expression levels of miR-146 and miR-155 in gingival crevicular fluid obtained 
from nondiabetic and type 2 diabetic periodontitis patients, at baseline and after non-surgical 
periodontal treatment in order to examine their association with periodontal status as well as 
oxidative stress. 
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Material and methods 
Study population 
Ninety-six subjects (44 males and 52 females, mean age 44.13±12.46), chosen among 
individuals with periodontitis (n= 48) and periodontally healthy controls (n=48) undergoing 
dental examination were included in this study. The study details were fully explained to the 
participants and the written consents were obtained. The study protocol was approved by the 
Ethical Research Committee of the School of Dental Medicine, University of Belgrade, 
Serbia (ethics approval № 36/3). 
Subjects were allocated in one of the four groups: CP  (24 healthy individuals with chronic 
periodontitis), CPDM  (24 patients with chronic periodontitis in association with DM type 2), 
PH  (24 healthy individuals with clinically healthy periodontium) or PHDM  group (24 
patients with clinically healthy periodontium in association with DM type 2). The sample size 
calculation was based on data of the previous studies on acute increase in miR-146a in 
inflamed periodontal tissue (Xie et al. 2011) and DM (Rong et al. 2013). A total number of 
96 participants (24 subjects per group) were needed to demonstrate a large difference (effect 
size-0.4) in GCF levels of miRs between groups with the test power of 90% and the alpha 
probability of 0.05.  Calculation was done using ANOVA for independent groups (statistical 
software package GPower 3.1). 
Inclusion criteria for subjects in PH group and CP group were as follows: ≥18 years of age, 
self-reported good general health, ≥ 20 erupted teeth excluding third molars, no periodontal 
treatment in previous six months.  Periodontally healthy participants that were included in 
this study had to have no gingival inflammation (gingival index, GI=0), and probing depth ≤ 
3 mm in every site (Himani et al. 2014). Participants with moderate or severe chronic 
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periodontitis had to have at least four sites with a probing pocket depth (PPD) of  ≥ 4 mm 
along with the presence of attachment loss of  ≥ 3 mm, and GI≥ 1 (Armitage 2004). 
The enrolled diabetic patients were diagnosed with type 2 DM for at least two years  and did 
not suffer with any additional systematic diseases. Only well controlled diabetic patients who 
had exhibited HbA1c levels of < 8% were eligible for the study (Ribeiro et al. 2011). 
Exclusion criteria for all participants were as follows: 1) smoking 2) presence of any other 
systemic diseases   3) the use of immunosuppressants, antibiotics, antiinflammatory drugs in 
the last six months 4) dietary supplementations  5) pregnancy or lactation. 
 
Clinical outcome variables  
Using a periodontal probe (PCPUNC 15, Hu Friedy, Chicago, USA), full mouth periodontal 
evaluation in six sites per tooth (mesiobuccal, midbuccal, distobuccal,mesiolingual, 
midlingual and distolingual), were done. The following clinical parameters were recorded: 1) 
probing pocket depth (PPD) - distance between the gingival margin and the bottom of the 
sulcus/pocket 2) clinical attachment level (CAL) - distance between the cemento - enamel 
junction and the depth at which the probe met resistance 3) bleeding on probing (BOP) 
(Ainamo & Bay 1975) - measured 15 seconds after probing and recorded as presence (1) or 
absence (0) 4) gingivitis index  (GI) (Loe & Silness 1963) and 5) plaque index (PI) (Silness 
& Loe 1964). 
The clinical parameters were recorded by the well experienced periodontist (NNJ). 
Intraexaminer calibration was performed twice, before and during the study to ensure 
intraexaminer consistency and reproducibility achieving Cohen’s Kappa of over 0.75 for each 
index.  Patients received hygiene instruction, scaling and root planning with ultrasonic device 
(Cavitron® Ultrasonic Inc., Long Island City, NY, USA) and hand instruments (Gracey 
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curretes, Hu-Friedy® Manufacturing Inc., Chicago, IL, USA), under local anesthesia, 
quadrant by quadrant, within two weeks. The periodontal therapy was carried out by the same 
clinician (NR).  The clinical measurements were recorded and GCF samples were taken from 
the sampling site at baseline and 6 weeks after the periodontal treatment. 
Gingival crevicular fluid (GCF) sampling 
Baseline, GCF samples were collected from two representative sites per participant, 24 hours 
after the clinical measurements were recorded. At post-treatment visit, GCF sampling was 
done prior the periodontal examination, but at same visit. Representative sites in 
periodontally healthy participants were mesiovestibular aspect of the right upper central 
incisor and right upper first molar. In patients with periodontitis, the two sites demonstrating 
the highest values of PPD and positive BOP were considered as representative. Before the 
sampling procedure, supragingival biofilm was gently removed from the sampling site, 
isolated with cotton rolls and dried. Sterile paper strip, Periopaper® ( Pro-Flow Corp., 
Amityville, NY, USA) was inserted into the gingival sulcus or periodontal pocket until mild 
resistance was felt, and left in place for 30 seconds. Strips contaminated by saliva or blood 
were excluded. Using a device for impedance measurement (Periotron 6000, ProFlow), the 
sampled fluid volume was measured, and the paper strips were pulled and inserted in sterile 
plastic tubes (Eppendorf®) containing 250µl RNAse free water. The samples were 
immediately frozen and stored at -70˚C until analyses. 
 
miR expression measurements 
Total RNA was extracted by using miRCURY™ RNA Isolation Kits – Biofluids (Exiqon 
A/S, Vedbaek, Denmark), according to the manufacturer’s instructions. 
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For the reaction of reverse transcription and quantitative real-time PCR (qRT-PCR)  we have 
used 10 ηg of total RNA, TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, California, USA), Taqman Universal master mix, No UNG 
amperase, and specific assays: hsa-miR-146a (ID:000468); hsa- miR-155(ID: 002623) and 
RNU6B (ID:001093), using standard temperature conditions. All reactions were run on Real 
Time PCR 7500 (Applied Biosystems, Foster City, California, USA). Expression levels of 
miRs were presented in relative units, and normalized to RNU6B, as the endogenous control. 
Comparison of RNU6B values between the groups showed no significant difference 
(p>0.05, Mann-Whitney test) 
 As a calibrator  reference (1X sample), the sample with the lowest relative quantity (RQ) 
value was used, and data were analyzed with the 7500 System SDS Software (Applied 
Biosystems, Foster City, California, USA), by comparative ΔΔCt method.  
SOD activity measurements 
SOD activity (%) in GCF was measured by SOD determination kit (Sigma-Aldrich, USA) 
according to manufacturer instructions.   
 
Statistical analysis 
Results were expressed as mean ± SD (clinical parameters) or as median values.  Patients 
characteristics were compared with nonparametric tests: Mann-Whitney for continuous and 
cross tables were constructed for dichotomous variables. Differences between groups in 
clinical parameters, miRs expression levels and activity of SOD were compared by one way 
ANOVA and Bonferroni post hoc test. The Spearman  and  Pearson  correlation tests were 
used to asses association between clinical variable (PPD) and SOD activity with miRs 
expression levels, respectively. Multiple linear regression analysis was used with the relative 
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expression of miRs as dependent and periodontitis, age  and gender as independent variables.  
In order to evaluate accuracy of the miR-146a and miR-155 in differentiating healthy from 
moderate to severe periodontitis patients, the receiver operating characteristic (ROC) curves 
were constructed by calculating the area under the curve (AUC) and identifying cut-off points 
to estimate the highest sensitivity and specificity as assessed by Youden’s index.  
Calculations were performed using software package (SPSS 18.0, IBM Statistics, USA) and 
differences were considered significant at p˂0.05 
 
Results 
Characteristics of the subjects 
The mean age of participants was significantly higher in the periodontitis groups, both in 
nondiabetic and type 2 diabetic,  in comparison with the groups of periodontally healthy 
participants. There were no significant differences between gender distribution within and 
between the groups. Patients showed moderate overweight with no differences in mean BMI 
between the groups observed (Table 1). The full mouth and sample sites PPD, CAL, BOP, 
GI, and PI were statistically greater, reflecting moderate periodontitis (CDC/AAP 
classification,  Page and Eke 2007) in the CP and CPDM groups compared to periodontally 
healthy groups (PH and PHDM) (p<0.01), 
Mean PPD and CAL values were significantly higher in periodontitis patients with type 2 
DM compared with nondiabetic periodontitis patients, while PI, GI, and BOP were not 
notably greater. All patients responded well to the non-surgical therapy as shown by 
decreased values of periodontal inflammation parameters (Table 1).  
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miR-146a and miR-155  expression levels in GCF of nondiabetic and type 2 diabetic 
subjects 
miR-146a levels were higher in type 2 diabetic compared to nondiabetic periodontally 
healthy patients . In CP and CPDM patients, miR-146a and miR-155 levels were significantly 
enhanced before non-surgical therapy while the levels decreased after the therapy to the 
levels comparable to periodontally healthy patients (Figure 1).  Multiple linear regression 
analyses revealed that periodontitis contributed significantly to the GCF expression levels of 
miR-146a and miR-155, when adjusting for age and gender (Table 2). There were no 
significant correlations between BMI values and investigated miRs (Supplementary material). 
The accuracy of miR-146a and miR-155 as GCF biomarkers of periodontitis is illustrated 
with ROC curves (Figure 2) and their respective values (Table 3). The ROC curves for both 
miRs in nondiabetic and type 2 diabetic patients showed a high accuracy for CP since AUC≥ 
0.9. miR-146a showed the best performance with a sensitivity of 100% , a specificity of 96% 
, at a cutoff point of  4.11 au (arbitrary units) in nondiabetic CP patients. In DM type 2 
patients, miR-155 showed better performance compared to miR-146a with a sensitivity of 
92%, a specificity of 100% at cut off point of 3.56 au (Table 3). miR-146a showed strong 
positive correlation with PPD  in both nondiabetic and type 2 diabetic periodontitis patients  
(Spearman r= 0.676 and r= 0.641, respectively, p< 0.01). Also, miR-155  showed  significant 
positive correlation with PPD in the group of  nondiabetic and type 2 diabetic periodontitis 
patients (Spearman r= 0.623 and r= 0.645, respectively, p< 0.01) . 
SOD activity  
Activity of major antioxidant enzyme, SOD, is significantly enhanced in CP and CPDM 
patients baseline and decreased six weeks after non-surgical therapy to the levels comparable 
to periodontally healthy (Figure 3). There are strong positive correlations of measured SOD 
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activity with miR-146a (Pearson r = 0.735, R
2
= 0.540, p< 0.001 in CP and Pearson r = 0.552, 
R
2
= 0.304, p < 0.001 in CPDM   patients) and miR-155 (Pearson r = 0.693, R
2
= 0.480, p< 
0.01 in CP and r = 0.623, R
2
= 0.388, p< 0.001 in CPDM patients). 
In silico analysis 
We used ComiR, a web-based software for the combinatorial prediction of mutual targets for 
miR-146a and miR-155 (Coronnello & Benos, 2013). ComiR calculates the probability of 
mRNAs to be targeted by a set of miRNAs. ComiR results for the two examined miRNAs 
from our study (expression levels input data), showed that SOD2 mRNA has the high 
probability to be recognized (equal abundance = 0.924) suggesting that miR-146a and miR-
155 in combination may have exceptionally strong probability to silence SOD2 transcription. 
 
Discussion 
Research based on miRs involvement in periodontal disease is in its infancy. This is, to our 
knowledge, the first study investigating potential of circulatory miRs, obtained in GCF, as 
biomarkers of periodontal disease. We have quantified miRs expression in GCF because it 
represents an inflammatory exudate that reflects an ongoing processes in inflamed 
periodontium more reliably than saliva or serum. miRs persist in body fluids as circulatory 
and exosomal  (Zhang et al. 2015) and participate in intercellular communication and  
immune regulatory function (Mittelbrunn and Sanchez-Madrid, 2012). Xie et al. showed that 
miR-146a and miR-155 are present  in periodontal tissues (Xie et al. 2011),  and since  
activation of macrophages is strongly dependent on their presence (Jablonski et al. 2016, 
O'Connell et al. 2007),  it could be assumed that inflammatory cells along with periodontal 
tissue cells and  systemic circulation represent possible sources of these miRNAs  in GCF.  
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Present results show that in nondiabetic and type 2 diabetic periodontitis patients, miR-146a 
and miR-155 show significantly higher levels compared with periodontally healthy  and that 
non-surgical periodontal therapy significantly reduced expression levels of both miRs in GCF 
reflecting the reduction of periodontal inflammation observed clinically. Considering the 
higher age of subjects in the periodontitis groups relative to the periodontally healthy 
subjects, we used multiple regression analyses adjusted for age in order our results to be 
applicable to younger patients, also.  
Levels of both, miR-146a and miR-155 could differentiate between healthy and moderate to 
severe periodontitis patients with high accuracy based on ROC curves analysis pointing at 
better performance of miR-146a in nondiabetic, and miR-155 in type 2 diabetic patients. In 
the previous studies, Motedayyen et al. showed upregulation of miR-146a in the gingiva of 
patients with chronic periodontitis while  Xie et al. showed upregulation  of miR-146a and 
downregulation of miR-155 levels in human inflamed gingival tissues  collected during 
periodontal flap surgery, and suggested a complex role of these miRs in gingival 
inflammation (Motedayyen et al. 2015, Xie et al. 2011). Also, Nahid et al. reported that  
periodontal pathogens induced in vitro persistent miR-146a  and less frequent miR-155 
expression in the mice maxilla and spleen (Nahid et al. 2011). The complexity of the miR-
146 and miR-155 actions in inflammation has been elegantly analyzed in work by Schulte et 
al. showing differential activation of miR-146 and miR-155 in murine macrophages (Schulte 
et al. 2013). Namely, the authors found that upon  LPS stimulation, miR-146 and miR-155 
act in two- tier manner: miR-146 is firstly activated at low LPS doses while miR-155 is 
gradually induced to full expression and represents limiter of proinflammatory gene 
expression when the miR-146-dependent anti-inflammatory effect has been breached. In 
order to investigate regulatory roles of these two miRs in periodontitis patients we used in 
silico analysis (Coronnello & Benos, 2013). The obtained results showed that these two miRs 
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in combination may have exceptionally strong probability to regulate SOD2 gene expression, 
suggesting miR-146a and miR-155 action in periodontal disease may involve regulation of 
oxidative stress. Namely, SOD2 is an mitochondrial antioxidant enzyme but mainly, all three 
types of SOD act in the same manner, by catalyzing neutralization of superoxide anions to 
oxygen and H2O2. In the present study, we measured SOD activity which reflects ROS 
generation, and found it to be highly positively correlated with miR-146a and miR-155 
expression levels in both, nondiabetic and type 2 diabetic periodontitis patients.  Indeed, in in 
vitro experiments (PC 12 cell line) showed that H2O2 ,  the product of SOD activity, induced 
expression of miR-146a (Ji et al. 2013) which then  feedback-represses  SOD2 gene 
expression.  Moreover, in the present study, reduction of inflammation in periodontal tissues 
after non-surgical therapy decreases levels of SOD activity as well as miR-146a and miR-155 
expressions. Very recent study showed that circulatory miR-21, miR-23a and miR-222 
regulate expression of SOD2, enzyme described as a cell protector in the diabetic 
cardiomyopathy (Dubois-Deruy et al. 2017, Shen et al. 2006). 
In GCF of type 2 diabetic patients with no signs of periodontal disease we found higher miR-
146a expression levels compared to nondiabetic periodontally healthy subjects. In line with 
this,  Rong et al (2013) found upregulated plasma circulatory levels of miR-146a in  DM type 
2 patients and suggested that expression of circulating miR-146a could hold predictive value 
for DM type 2 (Rong et al. 2013). Moreover, it seems that upregulation of miR-146a in DM 
exerts a protective effect by downregulating NF-κB’s target genes such as TNF alpha thereby 
reducing inflammation (Ye & Steinle 2016, Bhatt et al. 2016). In the present study, 
periodontitis patients with DM type 2, although with well controlled glycemia, showed more 
severe and extensive  periodontal inflammation. Usually, such findings were explained by 
increased inflammatory response to bacteria in DM (Graves et al. 2007) but mechanisms are 
not elucidated. The present results showing no difference in miR-146a expression in CPDM 
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compared to CP suggest complex engagement of miR-146a in immunomodulation depending 
on a different physiopathological context  (periodontitis and/or DM) and point at importance 
of miR-155 co-involvement in CPDM. Schulte et al. showed  that as a consequence of 
differential regulation, upregulated miR-146 under the invasion of bacteria may augment the 
initial LPS threshold required for miR-155 activation (Schulte et al. 2013). In such context, it 
seems possible that upregulated miR-146a in type 2 diabetic patients observed presently, 
when exposed to periodontal pathogens may postpone the anti-inflammatory effect of miR-
155 resulting in augmented inflammation in periodontal tissues. On the other hand, there is a 
proposition that circulatory miRs, released in the  body fluids could be taken up by neighbor 
or distant endothelial or immune cells acting as local or systemic communication tools (Ling 
& Groop 2009, Zhang et al. 2015). Under the diabetic condition, hyperglycemia or 
inflammation exert epigenetic alterations in host tissues which in turn change circulating 
miRs profiles and disseminate incorrect epigenetic signature to neighbor or distant cells, a 
phenomenon defined as epigenetic damage transmission (Prattichizzo et al. 2016). Therefore, 
it seems reasonable to assume that alteration of miR-146a expression in GCF of type 2 
diabetic patients could affect the inflammatory milleu of neighbour tissues resulting in more 
severe periodontal damage in DM patients.  
Limitation of the present study was that we didn’t evaluate serum miR-146a levels in order to 
investigate whether GCF miR-146a levels may reflect its systemic  levels  in type 2 diabetic 
patients. However, based on previous ( Rong et al.  2013 and  Baldeón et al. 2014) as well as 
on our present study, it may be possible to resume that obesity and/or dyslipidemia status, the 
stage of type 2 diabetes as well as an associate inflammatory events affect circulatory miR-
146a expression and therefore further investigation is needed in order to qualify miR-146a as 
reliable biomarker of type 2 DM.  
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 It is noteworthy that recent studies showed that host immune reactions against periodontal 
bacteria could promote the development of atherosclerosis associated with diabetic vascular 
disease (Aarabi et al. 2015, Reyes et al. 2013). The underlying mechanism proposed  include 
activation of  T helper17- inducing pathways involved in atherosclerotic plaque formation 
(Cai et al. 2014). Having in mind that periodontal bacteria may activate T helper17 by 
upregulating  miR-155 (Du et al. 2014), it seems reasonable to speculate that downregulation 
of miR-155, achieved by non-surgical periodontal therapy as shown presently,  may be 
beneficial in reducing risk for vascular disease development. 
In conclusion, the present study is the first to provide evidence that GCF expression levels of 
both miR-146a and miR-155, could be considered as potential biomarkers for periodontal 
disease in nondiabetic and type 2 diabetic periodontitis patients. Furthermore, we found the 
association of these gene regulators with oxidative stress mechanisms. Further elucidation of 
the detailed miRNA-146a and miRNA-155 mechanisms involved in the periodontal 
inflammation, especially in the setting of DM could expand the knowledge of the 
pathogenesis of periodontal disease and enable development of improved treatment 
strategies. 
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Table 1. Demographic characteristics and clinical parameters before and after treatment in the study groups 
Group Mean 
age 
and 
BMI  
 
Sex 
M/F 
 Before treatment After treatment 
 PPD (mm) CAL (mm) PI GI BOP (%) PPD (mm)  CAL (mm) PI GI BOP (%) 
CPDM 
N=24 
54.9 
25.45 
10/14 Full 
mouth 
4.79 ± 0.45# 5.16 ± 1.32# 2.38 ± 0.28# 2.35 ± 0.43# 72.5 ± 8.3# 3.15 ± 0.35‡ 4.37± 1.18‡ 0.46± 0.24‡ 0.67±0.56‡ 7.19±2.91‡ 
Sampled 
sites 
4.71 ± 0.33#* 6.17 ± 0.16#* 2.25 ± 0.36# 2.55 ± 0.50# 100.00 ± 0.00# 3.11 ± 0.51‡ 4.12 ± 1.43‡ 0.36± 0.46‡ 0.51±0.48‡ 0.33±0.34‡ 
CP 
N=24 
54.7 
27.31 
13/11 Full 
mouth 
4.42 ± 0.24** 4.92 ± 0.11** 2.21±0.18** 2.36±0.43** 76.5 ± 8.7** 3.26 ± 0.49‡ 4.19 ± 1.23‡ 0.50± 0.35‡ 0.86±0.32‡ 8.25±1.50‡ 
Sampled 
sites 
4.33 ± 0.22** 5.85 ± 0.35** 2.16±0.49** 2.58±0.39** 100.00 ±0.00** 2.34 ± 0.28‡ 4.11 ± 0.85‡ 0.39± 0.43‡ 0.54±0.55‡ 0.36±0.38‡ 
PHDM 
N=24 
33.2 
26.93 
10/14 Full 
mouth 
2.43 ± 0.42 2.40 ± 0.40 0.15 ± 0.10 0.18 ± 0.07 9.6 ± 4.3      
Sampled 
sites 
2.25 ± 0.23 0.63 ± 0.33 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00      
PH 
N=24 
33.4 
26.37 
11/13 Full 
mouth 
2.17 ± 0.30 2.24 ± 0.45 0.18 ± 0.08 0.16 ± 0.08 8.7 ± 5.4      
Sampled 
sites 
1.77 ± 0.24 0.48 ± 0.38 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00      
 
PPD, probing pocket depth; CAL, clinical attachment level; BOP, bleeding on probing; PI, plaque index; GI, gingivitis index 
Data are expressed as the mean ± standard deviation. ‡ p˂ 0.01 before vs after non-surgical treatment.** p˂ 0.01 CP compared to PH .# p<0.05 
CPDM compared to PHDM *p<0.05 CP compared to CPDM 
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Table 2. Multiple linear regression analysis of the association between miR-146a and 
miR-155 expression in gingival crevicular fluid (GCF) and periodontitis, adjusted for 
age and gender in nondiabetic and type2 diabetic patients 
 
Dependent variable Independent variable Estimate SE p value 95% CI 
 
miR-146a 
 
Periodontitis  0.950 0.806 < 0.001 3.629 to 6.879 
Age -0.118 0.032 0.422 -0.090 to 0.039 
Gender -0.071 0.426 0.363 -1.251 to 0.467 
 
miR-155 
 
Periodontitis  0.953 0.792 < 0.001 2.444 to 5.637 
Age -0.286 0.031 0.132 -0.112 to 0.015 
Gender -0.160 0.419 0.112 -1.522 to 0.166 
 
 
miR-146a 
(diabetic) 
Periodontitis -0.882 1.111 < 0.001 -6.518 to -2.041 
Age -0.174 0.046 0.454 -0.127 to 0.058 
Gender  0.075 0.527 0.485 -0.691 to 1.433 
 
miR-155 
(diabetic) 
Periodontitis -1.013 0.939 < 0.001 -6.983 to -3.199 
Age -0.211 0.039 0.269 -0.121 to 0.035 
Gender  0.063 0.445 0.473 -0.575 to 1.220 
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Table 3. Accuracy of miR-146a and miR-155 as biomarkers of chronic periodontitis in 
nondiabetic and type 2 diabetic patients 
 
 
 
 
AUC- area under the curve; CP- chronic periodontitis; CPDM- chronic periodontitis associated with 
diabetes mellitus type 2;   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarker               AUC                    Cutoff                   Sensitivity             1-Specificity      Youden`s 
                                                                                                                                                        index 
miR-146a (CP)        0.999                     4.11                         1.00                         0.04                    0.96 
 
miR-146a (CPDM) 0.952                     5.45                          0.88                        0.04                     0.83 
 
miR-155 (CP)          0.929                    2.70                          0.96                         0.21                     0.75 
 
miR-155 (CPDM)   0.988                     3.56                          0.92                        0.00                      0.92 
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Figure  1. Relative expression levels of microRNA-146a (miR-146a) and microRNA-155 
(miR-155) in GCF samples. Boxplots represent levels of miR-146a and miR-155  in GCF of 
periodontal healthy: nondiabetic (PH) and type 2 diabetic (PHDM) as well as in patients with 
periodontitis: nondiabetic (CP) and type 2 diabetic (CPDM) patients, baseline and six weeks 
after non-surgical therapy. 
 * p< 0.05   and ** p< 0.01  compared to PH;  
#
 p< 0.05  compared to PHDM patients; 
‡p< 0.01 before vs after non-surgical periodontal therapy. 
 
Figure  2. The receiver operating characteristic (ROC) curves for differentiating healthy from 
chronic periodontitis patients by using expression levels of microRNA-146a (miR-146a) in 
nondiabetic (A) and type 2 diabetic (B) patients and of microRNA-155 (miR-155) in 
nondiabetic (C) and type 2 diabetic (D) patients  obtained by logistic regression analysis. 
 
Figure  3.  The activity of superoxide dismutase (SOD) in GCF samples. Boxplots represent 
the SOD activity in GCF of periodontal healthy: nondiabetic (PH) and type 2 diabetic 
(PHDM) as well as in patients with periodontitis: nondiabetic (CP) and type 2 diabetic 
(CPDM) patients, baseline and after non-surgical therapy.   
** p< 0.01  compared to PH;   
#
p< 0.01   compared to PHDM patients; 
‡ p< 0.01 baseline vs after non-surgical periodontal therapy.  
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